Trials / Recruiting
RecruitingNCT05108519
Complications and Clinical Response in Cancer Patients Treated With Anti-VEGF-Related Therapies
A Prospective Study Evaluating Complications and Clinical Response in Cancer Patients Treated With Anti-VEGF-Related Therapies
- Status
- Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 170 (estimated)
- Sponsor
- M.D. Anderson Cancer Center · Academic / Other
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
This study collects information about complications and clinical response in cancer patients treated with anti-VEGF-related therapies. This study aims to observe side effects that may happen to patients with advanced cancer who are treated with anti-VEGF related therapy. This may help doctors learn if there are any relationships between these side effects and how the disease may respond to treatment.
Detailed description
PRIMARY OBJECTIVE: I. To explore the incidence of clinical complications associated with anti-VEGF-related therapies in cancer patients treated at Emory University and the University of Texas M.D. Anderson Cancer Center (MDACC). SECONDARY OBJECTIVES: I. To explore the correlation of clinical response rates to a novel blood pressure scoring system in cancer patients treated with anti-VEGF-related therapies. II. To explore the correlation of objective response to each toxicity grade 3 or higher in cancer patients treated with anti-VEGF-related therapies. III. To investigate the validity of a novel multi-parameter-based blood pressure scoring system and to determine if the new scoring method is concordant with the current Common Terminology Criteria for Adverse Events (CTCAE) method. OUTLINE: Patients' medical records are reviewed.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | Electronic Health Record Review | Medical records are reviewed |
Timeline
- Start date
- 2019-04-08
- Primary completion
- 2027-02-02
- Completion
- 2027-02-02
- First posted
- 2021-11-05
- Last updated
- 2026-02-19
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT05108519. Inclusion in this directory is not an endorsement.